Roche Gets CE Mark for Latest Covid-19 Nasal Antigen Test
02 February 2021 - 4:19AM
Dow Jones News
By Joshua Kirby
Roche Holding AG said Monday that it has received a CE mark for
its latest rapid Covid-19 test, which will now be available in
applicable European countries from the middle of this month.
The Swiss pharmaceuticals company said it had been granted the
European regulatory approval for its Rapid Antigen Test Nasal. The
new test collects samples from the frontal part of the nose, rather
than deeper inside, making it less uncomfortable. This means it can
also be carried out by patients themselves, reducing physical
contact between patients and health-care workers, Roche said.
The test follows a rapid antigen test launched by the company in
September. Both tests were launched in partnership with SD
Biosensor Inc., which is now applying for emergency approval for
the latest test from the U.S. Food & Drug Administration, Roche
added.
Write to Joshua Kirby at joshua.kirby@dowjones.com;
@joshualeokirby
(END) Dow Jones Newswires
February 01, 2021 12:04 ET (17:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024